In the second half of the year, the wave of drug companies leaving continued

"Pharmaceutical Network Industry Dynamics" Recently, Novarma Pharmaceuticals Asia Pacific, Middle East and Africa Regional President and Novart Group China President Yu Xudong for personal reasons decided to leave, related to the news that Novarma has issued a personnel announcement to employees.
, the departure of Yu Xudong has not yet been announced.
is unique, just a few days ago another multinational pharmaceutical company, Gilead (GILD. US) Global Vice President and China General Manager Luo Yongqing also confirmed his departure, and no new wheres have been announced.
fact, with the deepening of drug review reform since 2015, multinational pharmaceutical companies are facing great changes in China.
In the face of health-care negotiations and drug collection to drive down drug prices and China's policy of promoting the development of innovative drugs, patent dividends are no longer possible in the past, and the departure of senior executives has become the norm while multinational pharmaceutical companies have begun to adjust their strategies in China on a large scale.
at least 15 executives left in August, according to unstringed statistics.
is worth noting that at present, not only multinational companies in the flow of talent, the flow of local pharmaceutical companies also wave.
, according to incomplete statistics in the industry, in early August 2020 alone, a number of pharmaceutical listed company executives announced their resignations.
E.e., on August 10, fish leap medical announcement showed that the board of directors on the same day received the company's vice president (deputy general manager) Mr. Zhao Chunsheng written resignation report, Mr. Zhao Chunsheng for personal reasons requested to resign from his position as vice president (deputy general manager) of the company.
August 11, Step Pharmaceuticals announced that Ms. Wang Mei had applied to resign as the company's supervisor for personal reasons and would not hold any position at the company after her resignation.
There are also essence pharmaceutical Zhu Chunlin, Yang Xiaojun, Jingfeng Pharmaceutical Human Resources Director Zhang Junguo, Vice Zheng Pharmaceuticals Chairman / General Manager Sun Jilin, Beijing Lidman Chairman Lin Yu, Tonghua Dongbao Deputy General Manager Han Fengjun, Huangshan Capsule Independent Director Zhang Min, Qidan Pharmaceutical Supervisor Zhang Yousheng, Nanjing Pharmaceutical Director Han Dong, etc. all left in August.
addition, in July, a total of at least 17 pharmaceutical executives, including National Pharmaceuticals, Hengrui Pharmaceuticals and Gan Li Pharmaceuticals, left.
it is understood that the resignation of senior executives mainly concentrated in the deputy general manager, vice president - and the reasons for their departure mainly include work reasons, personal reasons, term of office expires, the division of work adjustment and so on.
fact, with the normalization of collection, pharmaceutical companies in order to maintain market share, had to maintain a lower price level, the direct strategy is to reduce sales costs, and change the past pharmaceutical representative marketing model.
process, the past thinking mode of pharmaceutical managers is no longer suitable for the current fierce competition situation of pharmaceutical enterprises.
, the industry believes that after the wave of departures in the first half of the year, the second half of the pharmaceutical executive adjustment will continue and become the norm.
background, the domestic pharmaceutical market to generic drug-led situation will be broken, drug prices will fall, drug quality will improve, the entire industry is facing the transformation and upgrading of the big changes.
, under the background of accelerating transformation and upgrading of China's pharmaceutical industry, pharmaceutical companies can survive and develop only by adjusting and adapting to new changes in a timely manner.